Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Beksac M, Eikema DJ, Koster L, Hulin C, Poiré X, Hamladji RM, Gromek T, Bazarbachi A, Ozkurt ZN, Pabst T, Ben Othman T, Finke J, Pirogova O, Wu D, Hayat A, Hilgendorf I, Tholouli E, de Wreede LC, Schönland S, Garderet L, Drozd-Sokolowska J, Raj K, Hayden PJ, Yakoub-Agha I, McLornan DP. Beksac M, et al. Bone Marrow Transplant. 2024 Apr;59(4):526-533. doi: 10.1038/s41409-023-02160-8. Epub 2024 Jan 31. Bone Marrow Transplant. 2024. PMID: 38297040 Free PMC article.
Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Ozcan M, Ustün C, Akçağlayan E, Akan H, Arslan O, Ilhan O, Beksaç M, Gürman G, Demirer T, Arat M, Celebi H, Konuk N, Uysal A, Koç H. Ozcan M, et al. Among authors: beksac m. Bone Marrow Transplant. 2001 Mar;27(5):499-505. doi: 10.1038/sj.bmt.1702816. Bone Marrow Transplant. 2001. PMID: 11313683 Clinical Trial.
Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M, Celebi H, Sargín D, Yalcin A, Topcuoglu P, Kalayoglu-Besisik S, Beyan C, Arslan O, Ozcan M, Gurman G, Ilhan O, Akan H. Beksac M, et al. Bone Marrow Transplant. 2003 May;31(10):897-904. doi: 10.1038/sj.bmt.1703930. Bone Marrow Transplant. 2003. PMID: 12748666 Clinical Trial.
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial.
Iacobelli S, de Wreede LC, Schönland S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Carella AM, Beksac M, Bosi A, Milone G, Corradini P, Friberg K, van Biezen A, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Garderet L, Kröger N, Gahrton G; EBMT CMWP, Plasma Cell Disorders Subcommittee. Iacobelli S, et al. Among authors: beksac m. Bone Marrow Transplant. 2015 Apr;50(4):505-10. doi: 10.1038/bmt.2014.310. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621805 Clinical Trial.
Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT.
Garderet L, Morris C, Beksac M, Gahrton G, Schönland S, Yakoub-Agha I, Hayden PJ. Garderet L, et al. Among authors: beksac m. Biol Blood Marrow Transplant. 2020 Sep;26(9):1559-1566. doi: 10.1016/j.bbmt.2020.04.016. Epub 2020 May 15. Biol Blood Marrow Transplant. 2020. PMID: 32417491 Free article. Review.
Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT).
Beksac M, Kröger N, Byrne JL, Ganser A, Yeğin ZA, Schönland S. Beksac M, et al. Bone Marrow Transplant. 2021 Mar;56(3):529-531. doi: 10.1038/s41409-020-01010-1. Epub 2020 Aug 2. Bone Marrow Transplant. 2021. PMID: 32741961 No abstract available.
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
Garderet L, Sbianchi G, Iacobelli S, Blaise D, Byrne JL, Remenyi P, Apperley JF, Touzeau C, Isaksson C, Browne P, Mayer J, Lenhoff S, Gonzalez Muniz S, Parody Porras R, Basak G, Poire X, Trneny M, Nagler A, Michieli M, Tanase A, Koster L, Hayden PJ, Beksac M, Schönland S, Yakoub-Agha I. Garderet L, et al. Among authors: beksac m. Eur J Haematol. 2021 May;106(5):708-715. doi: 10.1111/ejh.13602. Epub 2021 Feb 27. Eur J Haematol. 2021. PMID: 33580608
Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.
Hayden PJ, Eikema DJ, de Wreede LC, Koster L, Kröger N, Einsele H, Minnema M, Dominietto A, Potter M, Passweg J, Bermúdez A, Nguyen-Quoc S, Platzbecker U, Tischer J, Ciceri F, Veelken JH, Ljungman P, Schaap N, Forcade E, Carella AM, Gandemer V, Arcese W, Bloor A, Olivieri A, Vincent L, Beksac M, Schönland S, Yakoub-Agha I. Hayden PJ, et al. Among authors: beksac m. Bone Marrow Transplant. 2021 Oct;56(10):2367-2381. doi: 10.1038/s41409-021-01286-x. Epub 2021 May 11. Bone Marrow Transplant. 2021. PMID: 33976382 Free PMC article.
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Sahebi F, Eikema DJ, Koster L, Kroger N, Meijer E, van Doesum JA, Rovira M, Koc Y, Angelucci E, Blaise D, Sammassimo S, McDonald A, Arroyo CH, Sanchez JF, Forcade E, Castagna L, Stölzel F, Sanz J, Tischer J, Ciceri F, Valcarcel D, Proia A, Hayden PJ, Beksac M, Yakoub-Agha I, Schönland S. Sahebi F, et al. Among authors: beksac m. Transplant Cell Ther. 2021 Dec;27(12):999.e1-999.e10. doi: 10.1016/j.jtct.2021.09.008. Epub 2021 Sep 17. Transplant Cell Ther. 2021. PMID: 34543768 Free article.
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT.
Vincent L, Gras L, Ceballos P, Finke J, Passweg J, Harel S, Rosinol L, Minnema M, Teipel R, van Doesum J, Hänel M, Lenain P, Botella-Garcia C, Koenecke C, Ducastelle S, Sanz J, Schroyens W, Zuckerman T, Monaco F, Koster L, de Wreede L, Hayden PJ, Schönland S, Yakoub-Agha I, Beksac M. Vincent L, et al. Among authors: beksac m. Bone Marrow Transplant. 2022 Mar;57(3):499-501. doi: 10.1038/s41409-021-01560-y. Epub 2022 Jan 10. Bone Marrow Transplant. 2022. PMID: 35013536 No abstract available.
460 results